Synthorx, Inc., a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, Calif.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-750-4700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees25
OptionableNot Optionable
Synthorx (NASDAQ:THOR) Frequently Asked Questions
What is Synthorx's stock symbol?
Synthorx trades on the NASDAQ under the ticker symbol "THOR."
What price target have analysts set for THOR?
2 brokers have issued 12 month target prices for Synthorx's shares. Their predictions range from $21.00 to $30.00. On average, they expect Synthorx's share price to reach $25.50 in the next year. This suggests a possible upside of 18.7% from the stock's current price. View Analyst Price Targets for Synthorx.
What is the consensus analysts' recommendation for Synthorx?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthorx in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synthorx.
Has Synthorx been receiving favorable news coverage?
News headlines about THOR stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Synthorx earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near future.
Who are some of Synthorx's key competitors?
Some companies that are related to Synthorx include Amicus Therapeutics (FOLD), Heron Therapeutics (HRTX), Insmed (INSM), Madrigal Pharmaceuticals (MDGL), Portola Pharmaceuticals (PTLA), Xencor (XNCR), Supernus Pharmaceuticals (SUPN), Enanta Pharmaceuticals (ENTA), Endocyte (ECYT), Zogenix (ZGNX), The Medicines (MDCO), Mallinckrodt (MNK), AnaptysBio (ANAB), Biohaven Pharmaceutical (BHVN) and Myokardia (MYOK).
Who are Synthorx's key executives?
Synthorx's management team includes the folowing people:
- Dr. Laura K. Shawver, CEO, Pres & Director (Age 61)
- Dr. Marcos Milla Ph.D., Chief Scientific Officer (Age 56)
- Dr. Floyd E. Romesberg, Scientific Founder & Director (Age 53)
- Mr. Tighe M. Reardon C.F.A., CPA, CPA, Acting Chief Financial Officer (Age 43)
- Dr. Christian V. Kuhlen, Gen. Counsel (Age 46)
When did Synthorx IPO?
(THOR) raised $100 million in an IPO on Friday, December 7th 2018. The company issued 9,100,000 shares at a price of $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.
When did Synthorx's quiet period expire?
Synthorx's quiet period expired on Wednesday, January 16th. Synthorx had issued 11,912,727 shares in its public offering on December 7th. The total size of the offering was $131,039,997 based on an initial share price of $11.00. During Synthorx's quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
Who are Synthorx's major shareholders?
Synthorx's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include RA Capital Management LLC (35.47%), Orbimed Advisors LLC (19.39%), Matisse Capital (0.20%), Dean Capital Investments Management LLC (0.17%) and Monashee Investment Management LLC (0.09%). Company insiders that own Synthorx stock include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Institutional Ownership Trends for Synthorx.
Which institutional investors are buying Synthorx stock?
THOR stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Orbimed Advisors LLC, Matisse Capital, Dean Capital Investments Management LLC and Monashee Investment Management LLC. Company insiders that have bought Synthorx stock in the last two years include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Insider Buying and Selling for Synthorx.
How do I buy shares of Synthorx?
Shares of THOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synthorx's stock price today?
One share of THOR stock can currently be purchased for approximately $21.48.
How big of a company is Synthorx?
Synthorx has a market capitalization of $588.94 million. Synthorx employs 25 workers across the globe.
What is Synthorx's official website?
How can I contact Synthorx?
Synthorx's mailing address is 11099 NORTH TORREY PINES ROAD SUITE 290, LA JOLLA CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected]
MarketBeat Community Rating for Synthorx (NASDAQ THOR)
MarketBeat's community ratings are surveys of what our community members think about Synthorx and other stocks. Vote "Outperform" if you believe THOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
